PEP/NEWS — Peptide intel. Daily.

Use Code THOMAS20 for 20% off Timeline's Mitopure: http://timeline.com/thomas This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we are able to provide the con

Join Thrive Market today and get $20 off your first three orders plus a free $60 gift! http://thrivemarket.com/ThomasDeLauer This video does contain a paid partnership with a brand that helps to support this channel. It is because of brand

*Try Danger Creatine* https://dangercoffee.com/products/danger-creatine I have spent twenty years and millions of dollars testing every legal focus drug I could get my hands on. In this video, I break down which compounds actually work, wh

One of the biggest health mistakes after 50 is also one of the easiest to miss: how you drink water. A lot of people assume they’re fine if they’re not thirsty, but that mistake can quietly make some of the biggest problems of aging even wo

🎯 State of the Manscape — Should Men Trim, Shave, or Go Full Jungle? We did the State of the Bush for women - and you loved it. So now it's your turn, guys. Dr. Durst and Farideh Golembiewski, FNP, are breaking down everything men need to

Johnson details the nine evening protocols behind his reported 99.4th-percentile sleep score. The piece is useful for understanding how circadian anchoring and meal timing interact with sleep architecture.

The Forever Healthy Foundation has opened a free, evidence-graded encyclopedia covering more than 500 health and longevity interventions. Peptides, supplements, and first-generation rejuvenation therapies are all included.

May's roundup tracks longevity approaches that have moved beyond basic research toward clinical development. A fast read for staying current on what's advancing.

Peter Attia maps sleep medications by how quickly they work and which problems they target. The episode also reviews supplement evidence — useful context for anyone tracking sleep optimization research.

Harvard has released a longevity primer written for general readers. It marks a signal that the field is entering mainstream scientific discourse.

Lundbeck's bocunebart, a PACAP-pathway migraine drug, cleared mid-stage testing well enough for the company to push forward. It represents a different mechanism from the dominant anti-CGRP class.

Johnson argues that resting heart rate before sleep, waist circumference, and one more simple measure reveal more about health than most wearables. Zero cost, immediate feedback.

ADC Therapeutics lost more than half its market value after a Phase 3 blood cancer trial recorded a death rate analysts called difficult to accept. A reminder that novel oncology platforms still carry serious safety risk.

Most drug developers targeting PD-1/VEGF bispecifics are chasing lung cancer. Evidence, according to BioPharma Dive's analysis, may favor the liver instead. A strategic blind spot worth watching.

The longevity funding gap is real. Thalion is entering with a non-profit model aimed at the basic biology that VCs typically skip over.